Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
19 April 2022 |
Main ID: |
EUCTR2007-001666-32-ES |
Date of registration:
|
02/03/2010 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
A PHASE II, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR, CD20-POSITIVE B-CELL NON-HODGKIN’S LYMPHOMA THAT HAS PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY
ESTUDIO FASE II, ALEATORIZADO , DOBLE CIEGO, CONTROLADO CON PLACEBO PARA VALORAR LA SEGURIDAD, FARMACOCINÉTICA Y EFICACIA DE MULTIPLES DOSIS DE APOMAB ADMINISTRADAS POR VIA INTRAVENOSA EN COMBINACIÓN CON RITUXIMAB EN PACIENTES CON LINFOMA NON HODGKING FOLICULAR CON CELULAS B CD20 POSITIVAS QUE HAN PROGRESADO DESPUÉS DE UNA TERAPIA PREVIA CON RITUXIMAB
|
Scientific title:
|
A PHASE II, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR, CD20-POSITIVE B-CELL NON-HODGKIN’S LYMPHOMA THAT HAS PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY
ESTUDIO FASE II, ALEATORIZADO , DOBLE CIEGO, CONTROLADO CON PLACEBO PARA VALORAR LA SEGURIDAD, FARMACOCINÉTICA Y EFICACIA DE MULTIPLES DOSIS DE APOMAB ADMINISTRADAS POR VIA INTRAVENOSA EN COMBINACIÓN CON RITUXIMAB EN PACIENTES CON LINFOMA NON HODGKING FOLICULAR CON CELULAS B CD20 POSITIVAS QUE HAN PROGRESADO DESPUÉS DE UNA TERAPIA PREVIA CON RITUXIMAB
|
Date of first enrolment:
|
11/03/2008 |
Target sample size:
|
80 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001666-32 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III):
Therapeutic use (Phase IV):
|
|
Countries of recruitment
|
Belgium
|
Netherlands
|
Spain
|
United Kingdom
| | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: >Signed Informed Consent Form > Age =18 years >Diagnosis of follicular, CD20-positive B-cell NHL classified as Grade 1, 2, or 3a according to the WHO classification of malignant lymphomas >Progression of disease after an objective response (CR/CRu or PR) or SD lasting 6 months following completion of the most recent rituximab-containing regimen >A rituximab-containing regimen is defined as rituximab as a single agent during induction and/or maintenance, or in combination with other agents. >Measurable disease (according to modified IWG Criteria; see Appendix B) ECOG performance status of 0 or 1 (see Appendix D) >Life expectancy of 3 months >Willingness and capability to be accessible for follow-up until study termination or death >For patients of reproductive potential (both males and females), use of a reliable means of contraception (e.g., contraceptive pill, intrauterine device [IUD], barrier methods) throughout the trial and for 1 year following their last exposure to study treatment
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: >Grade 3b follicular lymphoma (according to the WHO classification) or histologic transformation from follicular lymphoma to aggressive lymphoma >Prior radiotherapy to a lesion(s) that will be used to assess response unless that lesion(s) shows clear evidence of lymphoma progression at baseline (i.e., =50% increase in the product of the longest perpendicular diameters of the lesion [greatest transverse diameter perpendicular diameter] when compared with the nadir of lesion dimensions following radiotherapy and 1.5 cm in the greatest transverse diameter) >Radiotherapy to a peripheral lesion within 14 days prior to Cycle 1, Day 1 or radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to Cycle 1, Day 1 >Prior radio-immunotherapy, including radiolabeled antibodies >Concurrent systemic corticosteroid therapy (except low-dose corticosteroid therapy used to treat an illness other than lymphoma) >Other invasive malignancies within 5 years prior to Cycle 1, Day 1 (other than basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated with curative intent) >History or evidence on physical examination of central nervous system (CNS) disease (e.g., primary brain tumor, CNS lymphoma, seizures not controlled with standard medical therapy, any brain metastases, or history of stroke) >Prior treatment with agonistic DR4 or DR5 antibodies or Apo2L/TRAIL >General Medical Concerns >Current or recent (within the 28 days prior to Cycle 1, Day 1) participation in another experimental drug study >Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, myocardial infarction within 1 year prior to Cycle 1, Day 1, unstable angina), New York Heart Association (NYHA; see Appendix E) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication within 1 year prior to Cycle1, Day 1, or Grade II or greater peripheral vascular disease (see Appendix F) at study entry >Active infection requiring parenteral antibiotics on Cycle 1, Day 1 Protocol: Apomab—Genentech, >Major surgical procedure (excluding lymph node biopsy) or significant traumatic injury within 28 days prior to Cycle 1, Day 1, or anticipation of need for major surgical procedure during the course of the study >Pregnancy (positive pregnancy test) or breast feeding >Serious, non-healing wound, ulcer, or bone fracture Laboratory values ANC 1500/L (may not be treated with G-CSF to maintain or exceed this level) Platelet count 75,000/L Total bilirubin1.6 mg/dL AST or ALT 2.5 the upper limit of normal (ULN) Serum creatinine 2.0 mg/dL or measured creatinine clearance =50 mL/min Hemoglobin 9 g/dL (may not be transfused or treated with erythropoietin to maintain or exceed this level) >Known human immunodeficiency virus (HIV) infection, seropositivity for hepatitis B surface antigen (HBsAg), hepatitis B IgG or IgM core antibody, or hepatitis C virus (HCV) antibody >History of other disease, metabolic dysfunction, physical finding, or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk from treatment complications
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Linfoma Non-Hodgking folicular con céluas B CD20 positivas MedDRA version: 9.1
Level: LLT
Classification code 10029593
Term: Non-Hodgkin's lymphoma NOS
|
Intervention(s)
|
Product Name: Apomab Pharmaceutical Form: Intravenous infusion Current Sponsor code: PRO95780 Other descriptive name: Apomab Concentration unit: mg/kg milligram(s)/kilogram Concentration type: up to Concentration number: 15- Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use
Trade Name: MabThera Product Name: Mabthera Pharmaceutical Form: Intravenous infusion Other descriptive name: Rituximab Concentration unit: mg/m2 milligram(s)/square meter Concentration type: equal Concentration number: 375-
|
Primary Outcome(s)
|
Main Objective: To evaluate the safety and tolerability of Apomab when combined with rituximab for the treatment of patients with relapsed follicular, CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). To make a preliminary assessment of the efficacy of Apomab when combined with rituximab for the treatment of patients with relapsed follicular, CD20-positive B-cell NHL, as measured byobjective response rate.
|
Primary end point(s): Objective response (defined as a PR or CR/CRu, occurring within 8 months post-randomization), as determined by the IRF using modified IWG Criteria
|
Secondary Objective: To make a preliminary assessment of the efficacy of Apomab when combined with rituximab for the treatment of patients with relapsed follicular, CD20-positive B-cell NHL, as measured by progression-free survival, duration of response, and overall survival. To evaluate the serum pharmacokinetics of Apomab and rituximab when combined for the treatment of patients with relapsed follicular, CD20-positive B-cell NHL.
|
Secondary ID(s)
|
APM4083g
|
2007-001666-32-NL
|
Source(s) of Monetary Support
|
Ethics review
|
Status: Approved
Approval date: 30/01/2008
Contact:
|
|